Dosing of Last Subjects in PK Study of VAL001

Respiratorius announces that the last subjects in the ongoing PK study of VAL001 has been dosed.

The tailored release profile of VAL001, combining immediate release and extended-release characteristics of sodium valproate, is evaluated in the pharmacokinetic (PK) study in healthy subjects. Preliminary results of the initial part of the study were evaluated during March 2022.

"We are very pleased with the recruitment and that we have been able to keep to the timelines while still some pandemic related restrictions being effective. Now a short follow-up period is remaining followed by analysis of the results and a formal closure of the study," says CEO Johan Drott in a comment.

This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-06-2022 10:59 CET.

Johan Drott
President Respiratorius AB
+46 709-22 41 40
johan.drott@respiratorius.com

Respiratorius AB (publ) is developing candidates for new effective drugs for the treatment of aggressive lymphoma. The company's business concept is to develop candidates for new drugs based on patent-pending substances, which in preclinical studies have shown superior results compared to what is currently considered standard treatment. For more information about Respiratorius, visit www.respiratorius.com.